J&J Seeks to Overturn $1.2 Billion Risperdal Lawsuit Verdict in Arkansas Supreme Court
Johnson & Johnson is knee-deep in an Arkansas federal court battle over its marketing of a drug tied to male breast growth and other side effects alleged in Risperdal lawsuit filings, FiercePharma.com reports.
A web article published on February 27th states that arguments from the U.S. drugmaker on why a $1.2 billion judgment from 2012 should be overturned began that day in Arkansas Supreme Court. According to the original verdict, Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals misled doctors about Risperdal’s benefits, and downplayed its risk for gynecomastia and other alleged complications. According to FiercePharma.com, 35 Attorney Generals in the U.S. recently filed a brief with the Court voicing their support for the two-year old decision, which they have asked the Court to uphold.
J&J Accused of Downplaying Risperdal Gynecomastia, other Side Effects
At the time, this multi-billion fine to Johnson & Johnson was its latest charge over Risperdal at the time. That was before the company agreed to pay more than $2.2 billion in November 2013 to resolve claims from the U.S. Department of Justice that this medication, along with several others, was promoted for off-label uses, however. Approved by the U.S. Food and Drug Administration (FDA) to treat schizophrenia and bipolar disorder in adults and adolescents, as well as irritability in children with autism, the federal government accused Johnson & Johnson of marketing the antipsychotic over the past decade to elderly patients with dementia and for pediatric uses. Risperdal in children was not cleared by the FDA until 2006.
According to court documents, Johnson & Johnson’s hearing in March will be its second this year involving Risperdal. The company appealed a similar verdict on January 28th in Louisiana Supreme Court, after successfully arguing against claims that its marketing of the drug violated a state law similar to the federal False Claims Act. As a result of a 4-3 decision, the Court’s $258 million fine from 2010 was tossed out.
In addition to federal claims over Risperdal, Johnson & Johnson is involved in at least 200 product liability lawsuits now consolidated in Pennsylvania state court. These claims are pending in the Philadelphia Court of Common Pleas after being filed by individuals who may have sustained antipsychotic drug injuries.
Call a Risperdal Lawyer Today
Contact our Firm to learn more about Risperdal lawsuits, and whether you may be eligible to file a claim over the antipsychotic. The Firm can be reached at (877) 779-1414.